Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina

Chantada, Guillermo; Fandiño, Adriana; Schvartzman, Enrique; Raslawski, Elsa; Schaiquevich, Paula; Manzitti, Julio

doi:10.1002/pbc.24857

Cited by 37 publications

(61 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This collaboration between governmental hospitals, local and international NGOs with prospective protocols has significantly improved survival in two decades, in addition to stimulating translational research and population-based incidence and survival studies. 3233,34 …”

Section: Epidemiologymentioning

confidence: 99%

Retinoblastoma

Dimaras

Corson

Cobrinik

et al. 2015

Nat Rev Dis Primers

Self Cite

450

390

View full text Add to dashboard Cite

Retinoblastoma is a rare cancer of the infant retina, which forms when both RB1 alleles mutate in a susceptible retinal cell, likely a cone photoreceptor precursor. Loss of the tumour suppressor functions of the retinoblastoma protein, pRB, leads to uncontrolled cell division and recurrent genomic changes during tumour progression. Although pRB is expressed in virtually all tissues, cone precursors have biochemical and molecular features that may sensitize to RB1 loss to enable tumourigenesis. Retinoblastoma is diagnosed in ~8,000 children each year worldwide. Patient survival is >95% in high-income countries, but <30% globally. However, outcomes are improving through increasing awareness for earlier diagnosis, new guidelines and sharing of expertise. Intra-arterial and intravitreal chemotherapy have emerged as promising methods to salvage eyes. Ongoing international collaborations will replace the multiple different classifications of eye involvement with standardized definitions to consistently assess eligibility, efficacy and safety of treatment options. Life-long follow-up is warranted since survivors of heritable retinoblastoma are at risk for developing second cancers. Defining the molecular consequences of RB1 loss in diverse tissues may open new avenues for treatment and prevention of retinoblastoma as well as second cancers in patients with germline RB1 mutations.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Retinoblastoma

Dimaras

Corson

Cobrinik

et al. 2015

Nat Rev Dis Primers

Self Cite

450

390

View full text Add to dashboard Cite

show abstract

“…Queremos mencionar que la medida de tendencia central utilizada por nosotros fue mediana y no promedio, principalmente por la distribución no homogénea de la muestra. Estos hallazgos hacen comparables nuestros números con los reportados en la literatura de países con mayor grado de desarrollo 2,8,[21][22][23] , y más altos que en reportes anteriores en Latinoamérica (80-94%) 4,8,24 . La supervivencia está asociada al estado de avance de la enfermedad 9 .…”

Section: Discussionunclassified

“…La mediana de edad en el diagnóstico de tumores bilaterales fue de 5,5 meses (0, [16][17][18][19][20][21][22][23][24], mientras que en los unilaterales fue de 11 meses (6-90) (p = 0,05).…”

Section: Lateralidad Y Focalidadunclassified

Manejo multidisciplinario en retinoblastoma: experiencia en 37 ojos

Ossandón

Zanolli

Pérez

et al. 2015

Archivos de la Sociedad Española de Oftalmología

View full text Add to dashboard Cite

“…This approach involves The initial reports on IVC for retinoblastoma led the way to a new era for retinoblastoma management [5][6][7][8]. Since then, there have been numerous publications on the efficacy of IVC for retinoblastoma from around the world [28][29][30][31][32][33]. The indications for various chemotherapy protocols can vary in different retinoblastoma centers.…”

Section: Chemotherapy For Retinoblastoma: Overviewmentioning

confidence: 98%